About Jaan Biotherapeutics
Jaan Biotherapeutics LLC (JBT), a preclinical stage company, is developing first-in-class regenerative therapies that reactive an evolutionary cardiac muscle regeneration process in human diseased adult heart that is active in human fetal tissue, but is inactive in the human adult heart. We have designed therapeutics that target carefully selected non-coding RNAs, known as microRNAS. MicroRNAs function in RNA silencing and post-transcriptional regulation of gene expression by modulating the activity of a number of genes and compensatory pathways. By modulating specific microRNAs, JBTs therapeutics reprogram a specific pool of cardiac myocytes in the adult heart to divide and potentially regenerate damaged heart muscle to treat cardiovascular diseases where cardiac muscle regeneration is required. JBT has two lead therapies that initially target three cardiovascular diseases:
Ischemic heart disease (IHD)- Drug Candidate JN-101
Cardiomyopathy associated with Duchenne muscular dystrophy (DMD)-Drug Candidate JN-101
Familial hypertrophic cardiomyopathy (HCM)-Drug candidate JN-210
Our lead candidate, JN-101, is ready for initiation of Investigational New Drug Application Studies.
State of Ownership